Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy

Diffuse large B-cell lymphomas (DLBCL)s, the most common type of Non-Hodgkin’s Lymphoma, constitute a heterogeneous group disorders including different disease sites, strikingly diverse molecular features and profound variability in clinical behavior. Molecular studies trials have partially revealed underlying causes for this made possible recognition some variants susceptible specific therapeutic approaches. The main histogenetic groups include germinal center, activated B cells, thymic cells terminally differentiated basic scheme where majority DLBCL cases can be ascribed. nodal/extranodal origin, mutational changes microenvironment peculiarities provide additional layers complexity. Here, we summarize status knowledge make proposals addressing future development targeted therapy DLBC cases.